glp-1 and gip/glp-1 receptor agonists Science Behind GLP 1 GIP Glucagon for Obesity Research | News & Announcements Potential Use of GLP-1 and

Despite the potential clinical benefits of GLP-1RA plus SGLT2i combination therapy in patients with T2DM, several factors may delay this combination to become a common practice soon, such as reimbursement and costs associated with polypharmacy

and increased insulin early AUC and C-peptide total and early AUCs

GLP-1= glucagon-like peptide-1

Read highlights from the released 2025 Standards of Care, including recommendations for CGM use in type 2 diabetes for the first time, the use of GLP-1 drugs for kidney and heart benefits and a warning of DKA risk in recreational marijuana use.

The World Obesity Atlas 2024 reports over 1.5 billion projected cases by 2035, highlighting its growing threat among pediatric and adult populations globally

The GLP-1 receptor agonists used clinically are based on exendin-4 and native GLP-1 and are available as formulations for daily or weekly s.c